  | Herkenne, S., Paques, C., Nivelles, O., Lion, M., BAJOU, K., Pollenus, T., Fontaine, M., Carmeliet, P., Martial, J., Nguyen, N.-Q.-N., & Struman, I. (2015). The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis. Science Signaling, 8 (403), 117. doi:10.1126/scisignal.aaa2403  Peer Reviewed verified by ORBi |
  | Amand, M., Erpicum, C., BAJOU, K., Cerignoli, F., Blacher, S., MARTIN, M., Dequiedt, F., Drion, P., Singh, P., Vandereyken, M., Musumeci, L., Moutschen, M., Gilles, C., Noël, A., & Rahmouni, S. (27 January 2014). DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase [Poster presentation]. GIGA Day 2014, Liège, Belgium. |
 | Bajou, K.* , Herkenne, S.* , Thijssen, V. L., D'Amico, S., Nguyen, N.-Q.-N., Bouche, A., Tabruyn, S., Srahna, M., Carabin, J.-Y., Nivelles, O., Paques, C., Cornelissen, Y., Lion, M., Noël, A., Gils, A., Vinckier, S., Declerck, P. J., Griffioen, A. W., Dewerchin, M., ... Struman, I. (2014). PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature Medicine, (7), 741. doi:10.1038/nm.3552 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Amand, M., Erpicum, C., BAJOU, K., Cerignoli, F., Blacher, S., Martin, M., Dequiedt, F., Drion, P., Singh, P., Zurashvili, T., Vandereyken, M., Musumeci, L., Mustelin, T., Moutschen, M., Gilles, C., Noël, A., & Rahmouni, S. (2014). DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase. Molecular Cancer. doi:10.1186/1476-4598-13-108 Peer Reviewed verified by ORBi |
Herkenne, S., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (19 May 2012). Implication of the PAI-1/uPA/uPAR signalosome in the antiangiogenic action of 16K prolactin [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (April 2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K prolactin [Poster presentation]. Biomedica, Liège, Belgium. |
Herkenne, S., Dalla Valle, A., Bajou, K., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2012). Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic action of 16K hPRL [Poster presentation]. Keystone symposia on Angiogenesis: Advances in Basic Science and Therapeutic Applications, Snowbird, United States - Utah. |
Struman, I., Martial, J., Bajou, K., & D'Amico, S. (25 August 2011). A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) – placental lactogen (PL)-family protein. |
Herkenne, S., Bajou, K., D'Amico, S., Nguyen, N.-Q.-N., Martial, J., & Struman, I. (2011). Implication of the PAI-1/uPA/uPAR complex in the effects of the antiangiogenic factor 16K hPRL [Poster presentation]. Giga cancer day, Liège, Belgium. |
Bajou, K., Herkenne, S., Thijssen, V. L., D'Amico, S., Srahna, M., Carabin, J.-Y., Gils, A., Declerck, P. J., Griffioen, A. W., Martial, J., & Struman, I. (January 2011). PAI-1 mediates antiangiogenic and fibrinolytic actions of prolactin/growth hormone 16-14K fragments [Poster presentation]. Giga-Day Symposia, Liège, Belgium. |
Herkenne, S., Bajou, K., D'Amico, S., Martial, J., & Struman, I. (21 May 2010). Study of the signalling pathway of 16K PRL and 14K GH for mediate their anti-angiogenic effect [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Kinet, V., Nguyen, N.-Q.-N., Sabatel, C., Bajou, K., Blacher, S., Noël, A., Martial, J., & Struman, I. (2009). Evaluation of the antitumor activity of 16K prolactin [Poster presentation]. Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Big Sky, United States - Montana. |
 | Bajou, K., Peng, H., Laug, W. E., Maillard, C., Noël, A., Foidart, J.-M., Martial, J., & Declerck, Y. A. (2008). Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell, 14 (4), 324-34. doi:10.1016/j.ccr.2008.08.012 Peer Reviewed verified by ORBi |
 | Jost, M., Maillard, C., Lecomte, J., Lambert, V., Tjwa, M., Blaise, P., Alvarez Gonzalez, M.-L., Bajou, K., Blacher, S., Motte, P., Humblet, C., Defresne, M.-P., Thiry, M., Frankenne, F., Gothot, A., Carmeliet, P., Rakic, J.-M., Foidart, J.-M., & Noël, A. (2007). Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I. American Journal of Pathology, 171 (4), 1369-80. doi:10.2353/ajpath.2007.070074 Peer Reviewed verified by ORBi |
 | Jost, M., Maillard, C., Lambert, V., Tjwa, M., Blaise, P., Lecomte, J., Bajou, K., Blacher, S., Motte, P., Humblet, C., Defresne, M.-P., Thiry, M., Frankenne, F., Gothot, A., Carmeliet, P., Rakic, J.-M., Foidart, J.-M., & Noël, A. (2006). Plasminogen activator inhibitor type I (PAI-1) controls bone marrow-dependent and independent vascularization. Acta Clinica Belgica, 61 (2, MAR-APR), 87. Peer Reviewed verified by ORBi |
Jost, M., Maillard, C., Lecomte, J., Lambert, V., Tjwa, M., Blaise, P., Alvarez Gonzalez, M.-L., Bajou, K., Blacher, S., Motte, P., Humblet, C., Defresne, M.-P., Thiry, M., Frankenne, F., Gothot, A., Carmeliet, P., RAKIC, J.-M., Foidart, J.-M., & Noël, A. (2006). Plasminogen activator inhibitor type 1 (PAI-1) controls bone marrow-dependent and independent vascularization [Poster presentation]. Meeting ABEC/BVSK. |
 | Masson, V., de la Ballina, L. R., Munaut, C., Wielockx, B., Jost, M., Maillard, C., Blacher, S., Bajou, K., Itoh, T., Itohara, S., Werb, Z., Libert, C., Foidart, J.-M., & Noël, A. (February 2005). Contribution of Host MMP-2 and MMP-9 to Promote Tumor Vascularization and Invasion of Malignant Keratinocytes. FASEB Journal, 19 (2), 234-6. doi:10.1096/fj.04-2140fje Peer Reviewed verified by ORBi |
 | Maillard, C., Jost, M., Romer, M. U., Brunner, N., Houard, X., Lejeune, A., Munaut, C., Bajou, K., Melen-Lamalle, L., Dano, K., Carmeliet, P., Fusenig, N. E., Foidart, J.-M., & Noël, A. (January 2005). Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia, 7 (1), 57-66. doi:10.1593/neo.04406 Peer Reviewed verified by ORBi |
 | Bajou, K., Maillard, C., Jost, M., Lijnen, R. H., Gils, A., Declerck, P., Carmeliet, P., Foidart, J.-M., & Noël, A. (09 September 2004). Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene, 23 (41), 6986-6990. doi:10.1038/sj.onc.1207859 Peer Reviewed verified by ORBi |
 | Rakic, J.-M., Lambert, V., Munaut, C., Bajou, K., Peyrollier, K., Alvarez Gonzalez, M.-L., Carmeliet, P., Foidart, J.-M., & Noël, A. (April 2003). Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization. Investigative Ophthalmology and Visual Science, 44 (4), 1732-1739. doi:10.1167/iovs.02-0809 Peer Reviewed verified by ORBi |
 | Rakic, J.-M., Maillard, C., Jost, M., Bajou, K., Masson, V., Devy, L., Lambert, V., Foidart, J.-M., & Noël, A. (March 2003). Role of plasminogen activator-plasmin system in tumor angiogenesis. Cellular and Molecular Life Sciences, 60 (3), 463-473. doi:10.1007/s000180300039 Peer Reviewed verified by ORBi |
 | Masson, V., Devy, L., Grignet, C., Berndt, S., Bajou, K., Blacher, S., Roland, G., Chang, Y., Fong, T., Carmeliet, P., Foidart, J.-M., & Noël, A. (28 October 2002). Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biological Procedures Online, 4, 24-31. doi:10.1251/bpo30 Peer Reviewed verified by ORBi |
 | Bajou, K., Lewalle, J. M., Martinez, C. R., Soria, C., Lu, H., Noël, A., & Foidart, J.-M. (10 August 2002). Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. International Journal of Cancer, 100 (5), 501-506. doi:10.1002/ijc.10487 Peer Reviewed verified by ORBi |
 | Devy, L., Blacher, S., Grignet, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J., Noël, A., & Foidart, J.-M. (February 2002). The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB Journal, 16 (2), 147-54. doi:10.1096/fj.01-0552com Peer Reviewed verified by ORBi |
 | Hajitou, A., Grignet, C., Devy, L., Berndt, S., Blacher, S., Deroanne, C., Bajou, K., Fong, T., Chiang, Y. W., Foidart, J.-M., & Noël, A. (2002). The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB Journal, 16, 1802-1804. doi:10.1096/fj.02-0109fje Peer Reviewed verified by ORBi |
Noël, A., Albert, V., Bajou, K., Bisson, C., Devy, L., Frankenne, F., Maquoi, E., Masson, V., Sounni, N. E., & Foidart, J.-M. (April 2001). New Functions of Stromal Proteases and Their Inhibitors in Tumor Progression. Surgical Oncology Clinics of North America, 10 (2), 417-32. doi:10.1016/s1055-3207(18)30073-5 Peer Reviewed verified by ORBi |
 | Lambert, V., Munaut, C., Frankenne, F., Bajou, K., Gerard, R., Carmeliet, P., Defresne, M.-P., Foidart, J.-M., Rakic, J.-M., & Noël, A. (April 2001). Influence of Plasminogen Activator Inhibitor Type 1 on Choroidal Neovascularization. FASEB Journal, 15 (6), 1021-7. doi:10.1096/fj.00-0393com Peer Reviewed verified by ORBi |
 | Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J.-M., & Noël, A. (10 February 2001). The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin. Implications for Antiangiogenic Strategies. Journal of Cell Biology, 152 (4), 777-84. doi:10.1083/jcb.152.4.777 Peer Reviewed verified by ORBi |
Bajou, K., Devy, L., Masson, V., Albert, V., Frankenne, F., Noël, A., & Foidart, J.-M. (2001). Role de l'inhibiteur des activateurs de plasminogene de type 1 dans l'angiogenese tumorale. Thérapie, 56 (5, Sep-Oct), 465-72. Peer Reviewed verified by ORBi |
Frankenne, F., Noël, A., Bajou, K., Sounni, N. E., Goffin, F., Masson, V., Munaut, C., Remacle, A., & Foidart, J.-M. (September 1999). Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy. Expert Opinion on Therapeutic Targets, 3 (3), 469-481 (13. doi:10.1517/14728222.3.3.469 Peer Reviewed verified by ORBi |
 | Noël, A., Bajou, K., Masson, V., Frankenne, F., Rakic, J.-M., Lambert, V., Carmeliet, P., & Foidart, J.-M. (1999). Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis and Proteolysis, 13 (6), 220-225. doi:10.1054/fipr.2000.0043 Peer reviewed |
 | Hajitou, A., Baramova, E., Bajou, K., Noë, V., Bruyneel, E., Mareel, M., Collette, J., Foidart, J.-M., & Calberg-Bacq, C.-M. (22 October 1998). Fgf-3 and Fgf-4 Elicit Distinct Oncogenic Properties in Mouse Mammary Myoepithelial Cells. Oncogene, 17 (16), 2059-71. doi:10.1038/sj.onc.1202126 Peer Reviewed verified by ORBi |
 | Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., & Foidart, J.-M. (August 1998). Absence of Host Plasminogen Activator Inhibitor 1 Prevents Cancer Invasion and Vascularization. Nature Medicine, 4 (8), 923-8. doi:10.1038/nm0898-923 Peer Reviewed verified by ORBi |
 | Lewalle, J. M., Cataldo, D., Bajou, K., Lambert, C. A., & Foidart, J.-M. (January 1998). Endothelial Cell Intracellular Ca2+ Concentration Is Increased Upon Breast Tumor Cell Contact and Mediates Tumor Cell Transendothelial Migration. Clinical and Experimental Metastasis, 16 (1), 21-9. doi:10.1023/A:1006555800862 Peer Reviewed verified by ORBi |
 | Lewalle, J. M., Bajou, K., Desreux, J., Mareel, M., Dejana, E., Noël, A., & Foidart, J.-M. (15 December 1997). Alteration of Interendothelial Adherens Junctions Following Tumor Cell-Endothelial Cell Interaction in Vitro. Experimental Cell Research, 237 (2), 347-56. doi:10.1006/excr.1997.3799 Peer Reviewed verified by ORBi |
 | Baramova, E. N., Bajou, K., Remacle, A., L'Hoir, C., Krell, H. W., Weidle, U. H., Noël, A., & Foidart, J.-M. (24 March 1997). Involvement of Pa/Plasmin System in the Processing of Pro-Mmp-9 and in the Second Step of Pro-Mmp-2 Activation. FEBS Letters, 405 (2), 157-62. doi:10.1016/S0014-5793(97)00175-0 Peer Reviewed verified by ORBi |
 | Devy, L., Noël, A., Baramova, E. N., Bajou, K., Trentesaux, C., Jardillier, J. C., Foidart, J.-M., & Jeannesson, P. (1997). Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells. Biochemical and Biophysical Research Communications, 238, 842-846. doi:10.1006/bbrc.1997.7398 Peer reviewed |
 | Noël, A., Gilles, C., Bajou, K., Devy, L., Kebers, F., Lewalle, J. M., Maquoi, E., Munaut, C., Remacle, A., & Foidart, J.-M. (1997). Emerging Roles for Proteinases in Cancer. Invasion and Metastasis, 17 (5), 221-39. Peer Reviewed verified by ORBi |
Michiels, C., Arnould, T., Janssens, D., Bajou, K., Geron, I., & Remacle, R. (June 1996). Interactions between endothelial cells and smooth muscle cells after their activation by hypoxia. A possible etiology for venous disease. International Angiology: A Journal of the International Union of Angiology, 15 (5), 124-130. Peer Reviewed verified by ORBi |